Overall rank by patents
#11,551
of 50,000 tracked assignees
USPTO PatentsView assignee record - 26 granted patents across 7 technology areas, recorded in grant years 2019–2024. Grant-trend analysis is cross-referenced to USPTO Patent Public Search; it does not measure application filings, current R&D, or legal strength. Primary class: A61J (CONTAINERS SPECIALLY ADAPTED FOR MEDICAL OR PHARMACEUTICAL PURPOSES; DEVICES OR METHODS SPECIALLY ADAPTED FOR BRINGING PHARMACEUTICAL PRODUCTS INTO PARTICULAR PHYSICAL OR ADMINISTERING FORMS; DEVICES ).
The verdict
According to USPTO PatentsView, ART ranks #11,551 of 50,000 tracked US assignees by granted-patent volume, with 26 patents across 7 technology areas.
ART Medical Ltd. has been granted 26 US utility patents between 2019 and 2024, placing ART Medical Ltd. at #11,551 of 50,000 across all assignees tracked by PlainPatent. This portfolio spans 7 distinct Cooperative Patent Classification (CPC) subclasses, averaging 20.0 claims per patent with primary concentration in A61J (CONTAINERS SPECIALLY ADAPTED FOR MEDICAL OR PHARMACEUTICAL PURPOSES; DEVICES OR METHODS SPECIALLY ADAPTED FOR BRINGING PHARMACEUTICAL PRODUCTS INTO PARTICULAR PHYSICAL OR ADMINISTERING FORMS; DEVICES ). As a Foreign Corporation, ART Medical Ltd. is one of the more focused assignees in the PatentsView dataset. By volume, ART sits between Amobee, Inc. (26 patents, rank #11,532) and Atomic Energy OF Canada Limited/ènergie Atomique DU Canada Limitèe (26 patents, rank #11,540) - the closest US assignees by grant volume. The composite Innovation Score of 39.4/100 blends portfolio volume, grant velocity, technology breadth, and claim depth into a single comparable measure drawn directly from USPTO PatentsView records.
Grant cadence records the difference between two grant-year windows. Between 2020 and 2024 the company received 25 grants, compared with 1 in the 2015–2019 window, a +2400% shift in five-year grant velocity. Both windows cover five complete grant years; the latest PatentsView year is a partial release and is excluded from this comparison, though it still appears in the yearly table and chart below. Grant timing can lag the related application by years, so this comparison does not establish current R&D spending, strategic intent, or a company’s application activity. The Foreign Corporation classification provides context for the assignee record, not a conclusion about its business strategy.
Claim depth and technology breadth describe this aggregate record. ART Medical Ltd.'s 20.0 average claims per patent is an average count, not a measure of claim scope, legal strength, enforceability, or design-around risk. The record spans 7 CPC subclasses. Combined with portfolio volume, these figures let readers compare the documented grant records of assignees in similar technology classes.
Granted US patents 2015–2025 versus its nearest-ranked assignees by volume, this company marked ◀
AMOBEE, INC.
26 patents
ANDREAS FAHL MEDIZINTECHNIK-VERTRIEB GMBH
26 patents
AOD Holdings, LLC
26 patents
AQUA CO., LTD.
26 patents
ARTURO SALICE S.P.A.
26 patents
ASSA ABLOY Access and Egress Hardware Group, Inc.
26 patents
ASTRIUM SAS
26 patents
ATOMIC ENERGY OF CANADA LIMITED/ÈNERGIE ATOMIQUE DU CANADA LIMITÈE
26 patents
ART MEDICAL Ltd.
26 patents
What this shows ART holds 26 patents at rank #11,536, shown against the 8 assignees closest to it in grant volume rather than the industry's largest filers.
By rank, the assignees closest to #11,536 in granted patent volume.
Other assignees with the most granted patents in ART's primary technology class.
ART's Innovation Score vs. every tracked assignee
Composite of portfolio volume, grant velocity, technology breadth, and claim depth (0–100)
39 Top 38% higher than 62% of 50,000 US assignees
Each bar is a band; taller bars hold more US assignees. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count, share, and where it sits relative to this entry.
Source USPTO PatentsView, PlainPatent Innovation Score · 2015–2025
Teal-shaded recent years (2020–present) versus the 2019–2019 baseline. Full figures in the table below.
| Year | Patents Granted | Share of Period |
|---|---|---|
| 2019 | 1 | 3.8% |
| 2020 | 4 | 15.4% |
| 2021 | 8 | 30.8% |
| 2022 | 6 | 23.1% |
| 2023 | 5 | 19.2% |
| 2024 | 2 | 7.7% |
Top 7 of 7 technology areas
Historical grant data only; it does not rate legal strength or current strategy.
Overall rank by patents
#11,551
of 50,000 tracked assignees
39.4 out of 100
How to use this portfolio
ART's 26 grants land it in the top 38% by Innovation Score, but volume alone doesn't tell you where the strength sits.
Patent counts and the Innovation Score measure patenting activity, not commercial success or the legal strength of any patent. Many patents are filed defensively. Verify the status of an individual patent against official USPTO records.
Every figure on PlainPatent is rendered directly from USPTO source data, no number is typed in by an editor. This page draws directly on USPTO source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of May 2026.